The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.

With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.

Once viable long-acting HIV prevention and treatment options have reached the market, what will be their true impact? Leading HIV clinician-researcher Anton Pozniak, M.D., shares his expertise.

The first large-scale clinical trial to study kidney transplantations between people with HIV has begun at clinical centers across the U.S.

There is a great deal of interest in exploring the potential of gene therapy to cure HIV and multiple gene therapy strategies are under investigation.

The death toll from HIV/AIDS continues to decline, but more than 36 million people are still living with HIV. A researcher explains why the work for a cure is painstaking.

Last year's antiretroviral darling was dolutegravir (Tivicay, DTG). Now, the limelight has shifted to its integrase sibling, bictegravir. Requiring no pharmacological boosting, boasting a high barrier to resistance, and in early 2018 available co-for...

Bictegravir, an emerging integrase inhibitor that is co-formulated with two other anti-HIV drugs, showed an efficacy similar to Tivicay (dolutegravir) in a phase III clinical trial.